scPharmaceuticals (NASDAQ:SCPH) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.38) by 2.63 percent. This is a 54.17 percent decrease over losses of $(0.24) per share from the same period last year.
Crown Holdings Crowned With Higher Upside: Analyst Forecasts A Royal 2H Performance
Mizuho analyst Christopher Parkinson reiterated a Buy rating on Crown Holdings, Inc.(NYSE:CCK), raising the price target to $108 from $103. Given…
